MOLECULAR SCREENING SHARED RESOURCE (MSSR) ABSTRACT The goal of the UCLA Jonsson Comprehensive Cancer Center (JCCC) Molecular Screening Shared Resource (MSSR) is to provide transformative high throughput screening (HTS) capabilities to the UCLA research community and beyond. The MSSR offers a comprehensive array of HTS services enabling JCCC investigators to discover new molecular targets, identify small molecule drugs for these targets, and characterize and optimize candidate agents in preparation for clinical assessments. Established in 2003, the MSSR has grown from 2,085 sf. in 2013 to 3,600 sf. of BSL2+ compatible space in 2017. The cumulative number of faculty users nearly tripled from 86 to 237 users in the prior project period. During the last six years, the cumulative amount of extramural cancer relevant funding brought to UCLA by leveraging MSSR capabilities reached ~$180M. Since 2013, 20 JCCC members used the MSSR, representing 70% of overall usage, with 40% from members with peer-reviewed funding. MSSR collaborations contributed to 68 cancer-relevant publications from 2013 ? 2018 with 43% of these in high impact (IF ?10, or field leading) journals. A comprehensive set of services cover assay development, HTS, data analysis, and follow-up work, such as potency and toxicity determinations and selectivity testing. The MSSR offers access to 200,000 compounds in various libraries for chemical genomics, repurposing, and drug discovery. The MSSR also offers a wide array of functional genomics libraries, including human genome-wide arrayed CRISPR and shRNA lentiviral constructs, siRNAs covering the mouse and human druggable genomes, and genome-wide cDNA libraries in lentiviral and transfection ready formats. Projects are research partnerships between MSSR staff and JCCC faculty members, supported by three expert MSSR scientists on four fully automated, robotic screening systems, with a per diem capacity exceeding 100K samples in 384 well plate format. All plate reader based assays and plate formats are addressable, as are advanced assay readouts, such as phenotypic screening by confocal spinning disk microscopy. The MSSR follows a collaborative model that integrates the user into a project team consisting of a JCCC investigator, MSSR leadership, and MSSR scientists. The integration of the users into the project team also brings the necessary biological knowledge to the project while keeping the MSSR headcount and associated cost low but scalable with demand. Moreover, this is an excellent educational opportunity for students to learn in one-on-one training from MSSR experts. All projects utilize best industry practices including the generation of SOPs and milestone driven project management. MSSR Director Robert Damoiseaux, PhD (ZY) is an internationally known expert in HTS with an industry background who frequently provides talks at national meetings and guides each project in the MSSR, ensuring research excellence. The year 2017 was pivotal for the MSSR, with the first drug based on a molecule discovered at the MSSR entering clinical trials for myelodysplastic syndrome and acute myeloid leukemia.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016042-44
Application #
9936716
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2020-04-01
Budget End
2021-03-31
Support Year
44
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of California Los Angeles
Department
Type
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Chua, Bernadette Anne; Ngo, Jamie Ann; Situ, Kathy et al. (2018) Protein S and Gas6 induce efferocytosis of HIV-1-infected cells. Virology 515:176-190
Stanton, Annette L; Wiley, Joshua F; Krull, Jennifer L et al. (2018) Cancer-related coping processes as predictors of depressive symptoms, trajectories, and episodes. J Consult Clin Psychol 86:820-830
Glenn, Beth A; Hamilton, Ann S; Nonzee, Narissa J et al. (2018) Obesity, physical activity, and dietary behaviors in an ethnically-diverse sample of cancer survivors with early onset disease. J Psychosoc Oncol 36:418-436
Tsai, Wen-Ting K; Wu, Anna M (2018) Aligning physics and physiology: Engineering antibodies for radionuclide delivery. J Labelled Comp Radiopharm 61:693-714
Lisova, Ksenia; Sergeev, Maxim; Evans-Axelsson, Susan et al. (2018) Microscale radiosynthesis, preclinical imaging and dosimetry study of [18F]AMBF3-TATE: A potential PET tracer for clinical imaging of somatostatin receptors. Nucl Med Biol 61:36-44
Chang, Yu-Ling; Rossetti, Maura; Vlamakis, Hera et al. (2018) A screen of Crohn's disease-associated microbial metabolites identifies ascorbate as a novel metabolic inhibitor of activated human T cells. Mucosal Immunol :
Kiertscher, Sylvia M; Gangalum, Pallavi R; Ibrahim, Grace et al. (2018) A Prospective Study of Humoral and Cellular Immune Responses to Hepatitis B Vaccination in Habitual Marijuana Smokers. J Neuroimmune Pharmacol 13:219-229
Jia, Qingmei; Bowen, Richard; Dillon, Barbara Jane et al. (2018) Single vector platform vaccine protects against lethal respiratory challenge with Tier 1 select agents of anthrax, plague, and tularemia. Sci Rep 8:7009
Van, Christina; Condro, Michael C; Lov, Kenny et al. (2018) PACAP/PAC1 Regulation of Inflammation via Catecholaminergic Neurons in a Model of Multiple Sclerosis. J Mol Neurosci :
Leoh, Lai Sum; Kim, Yoon Kyung; Candelaria, Pierre V et al. (2018) Efficacy and Mechanism of Antitumor Activity of an Antibody Targeting Transferrin Receptor 1 in Mouse Models of Human Multiple Myeloma. J Immunol 200:3485-3494

Showing the most recent 10 out of 767 publications